Initial First-In-Human Results: CD33-Deleted Hematopoietic Stem and Progenitor Cells Display Normal Engraftment after Hematopoietic Cell Transplant (HCT) and Tolerate Post-HCT Gemtuzumab Ozogamicin (GO) without Cytopenias
Publications
Filter by:
Clear all filters
Search Publications
Leveraging Human Genetics To Advance Cell Therapies For Treatment Of Blood Cancers
A machine learning approach incorporating germline information improves genotyping of CRISPR-Cas9 gene editing events at single cell resolution
Efficient Multiplex Gene Editing of CD33 and CLL-1 in Human Hematopoietic Stem Cells Enables the Potential of Next-Generation Transplants for AML Treatment
Functional Validation of Single Domain Antibody-Derived CD33 Specific CAR-T Cells for the Treatment of Acute Myeloid Leukemia
Multiplex deletion of myeloid antigens by base editing in human hematopoietic stem and progenitor cells (HSPCs) enables potential for next generation transplant for acute myeloid leukemia (AML) treatment
Efficient knockout of both CD33 and CLL-1 by multiplex genome editing of human hematopoietic stem cells enhances the potential of next- generation transplants for acute myeloid leukemia (AML) treatment
Automated Closed Cell Processing System De-Risks Gene-Edited CD34+ Hematopoietic Stem Cell Manufacturing
TransACT enhances detection and characterization of translocation events from high-throughput sequencing data at base-pair resolution for gene editing products